Speaker
Edoardo Renaldin
(Paul Scherrer Institute)
Summary
166Ho is a promising therapeutic radionuclide thanks to its high-energy β⁻ emissions, but clinical supplies are typically carrier-added and direct production co-generates long-lived 166mHo. We address this by pursuing an indirect route: irradiating enriched 164Dy₂O₃ to enable large-scale production of non-carrier-added 166Ho without 166mHo. This strategy also supports a practical generator concept.
| Are you interested/eligible for the Young Session? | Yes, I am eligible and interested in participating |
|---|
Author
Edoardo Renaldin
(Paul Scherrer Institute)
Co-authors
Mr
Chen Yan
(University of Bern)
Nick van der Meulen
(Paul Scherrer Institute)
Prof.
Robert Eichler
(Paul Scherrer Institute)
Ulli Köster
(Institut Laue Langevin)
Zeynep Talip
(Paul Scherrer Institute)
